Metastatic Castrate Sensitive Prostate Cancer Mcspc clinical trials

Explore recruiting metastatic castrate sensitive prostate cancer mcspc clinical trials.

Recruiting metastatic castrate sensitive prostate cancer mcspc studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Castrate Sensitive Prostate Cancer Mcspc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase 2 trial of BMS-986365 in mCSPC patients with suboptimal PSA-response after 7 months of Androgen Deprivation Therapy (ADT) plus Androgen Receptor Pathway Inhibition (ARPI).

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Metastatic Castrate Sensitive Prostate Cancer Mcspc trials by city

Metastatic Castrate Sensitive Prostate Cancer Mcspc clinical trials

Recruiting metastatic castrate sensitive prostate cancer mcspc studies right now

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)

Also recruiting in Europe

A phase 2 trial of BMS-986365 in mCSPC patients with suboptimal PSA-response after 7 months of Androgen Deprivation Therapy (ADT) plus Androgen Receptor Pathway Inhibition (ARPI).

Metastatic Castrate Sensitive Prostate Cancer Mcspc trials by city

Other conditions